Custom Search


Tuesday 01 May 2001

The apparent effects of ziprasidone on plasma lipids and glucose.

By: Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM.

J Clin Psychiatry 2001 May;62(5):347-9

BACKGROUND: We examined the effects of ziprasidone on body mass index (BMI) and serum levels of glucose, cholesterol, and triglycerides. METHOD: As part of a multicenter study examining different strategies for switching to ziprasidone from other antipsychotics, we evaluated weight and serum glucose, cholesterol, and triglyceride measurements at baseline and following 6 weeks on ziprasidone treatment in 37 patients at our site. RESULTS: Short-term treatment with ziprasidone appeared to lead to significant reduction in serum cholesterol (p < .001) and triglyceride levels (p = .018) independent of changes in BMI. Ziprasidone treatment appeared to have no significant effect on BMI or glucose level, perhaps due to the small number of subjects. CONCLUSION: Ziprasidone appears to independently lead to a lowering of serum lipid levels.

Use of this site is subject to the following terms of use